APL-101: c-Met inhibitor
APL-101 is a novel, highly selective small molecule c-Met inhibitor (c-METi) that targets the c-Met-dysregulated pathway in several tumors. APL-101 has demonstrated tumor inhibitory effect in a variety of human primary gastric, hepatic, pancreatic and lung tumor xenograft animal models with c-Met dysregulations.
c-Met, which is also known as the hepatocyte growth factor receptor, or HGFR, is a signaling receptor tyrosine kinase that has specific roles in normal mammalian growth and development. However, the c-Met pathway has also been shown to function abnormally in a range of different cancers through c-Met gene amplification, over-expression, and gene mutations, deletions, and insertions. The abnormal activation of c-Met has been demonstrated in many cancer including kidney, lung, gastric, colorectal, esophageal and brain cancer. Dysregulated c-Met plays a major role in cancer development including tumor growth, survival, invasions, and metastasis.
APL-101 has demonstrated tumor inhibitory effect in a variety of human primary gastric, hepatic, pancreatic and lung tumor xenograft animal models with c-Met dysregulations.
Apollomics retains worldwide rights to APL-101 outside of China.
APL-101 is currently being evaluated in several ongoing clinical trials. For additional information, please click on the trial links below.
Sparta Phase 2 Clinical Trial
An international multicenter, open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of APL-101.
- Non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations
- Glioblastoma multiforme with MET amplifications and fusions
- Solid tumors with MET amplifications and fusions
|Agents:||APL-101 + APL-103 (EGFR inhibitor)|
China Partner & Clinical Trials:
Beijing Pearl Biotechnology Co. Ltd. has development rights in China for APL-101 where it is referred to as PLB1001.